People
XIONG Xiaoli
Title:Principle Investigator
Subject:
Email:xiong_xiaoli@gibh.ac.cn
Address:Kaiyuan Dadao 190,510530,Guangzhou,China
Study/Work Experience

2020 – now

Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences/ Principal Investigator

2018 – 2020

MRC Laboratory of Molecular Biology (UK)/ Postdoctoral scientist

2016 – 2018

University of Washington (USA)/ Senior Fellow

2011 – 2016

The Francis Crick Institute (UK)/ Career Development Fellow

2007 – 2011

University of Bristol (UK)/ Pathology and Microbiology/ Doctor of Philosophy

2004 – 2007

University of Bristol (UK)/ Biochemistry/ Bachelor of Science

Research Areas

Xiaoli “Alex” Xiong is a principal investigator at the Center for Infection and Immunity in the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, and a principal investigator at the State Key Laboratory of Respiratory Diseases. Dr Xiong primarily uses biochemistry and structural biology techniques to study pathogenesis mechanisms of respiratory viruses and bacteria.

Dr Xiong has studied the assembly mechanism of influenza virus by elucidating the full-length structure of the influenza virus M1 protein. He has also studied structural features of complexes formed between hemagglutinins and receptors of various influenza viruses such as H5N1, H7N9, H10N8, and H3N2. These researches inform the mechanisms through which receptor binding changes contribute to cross-species transmission of multiple influenza viruses.

Since 2016, he has conducted researches on spike (S) proteins of various coronaviruses, including SARS-CoV-1, SARS-CoV-2 and porcine deltacoronavirus. These researches inform coronavirus invasion and immune recognition mechanisms. Since the COVID-19 pandemic, he has studied the mechanisms of COVID-19 population immunity and SARS-CoV-2 immune evasion. In collaboration with Professor Zhong Nanshan, recipient of the Medal of the Republic, Professor Xiong’s research team has completed the preclinical study of the Mpro inhibitor RAY1216, which has been approved and marketed as “Leritrelvir” to treat COVID-19 in China. He has published over 40 articles in influential journals such as Nature, Cell, Nature Microbiology, Nature Structural & Molecular Biology, PNAS, and NAR. His researches have been cited over 5000 times.


Academic Performance
Representative Papers

1.    Xue, L.#, Chang, T.#, Li, Z., Wang, C., Zhao, H., Li, M., Tang, P., Wen, X., Yu, M., Wu, J., Bao, X., Wang, X., Gong, P., He, J., Chen, X.*,Xiong, X.*(2024) Cryo-EM structures of Thogoto virus polymerase reveal unique RNA transcription and replication mechanisms among orthomyxoviruses.Nature Communications15: 4620

2.    Liu, B.#, Niu, X.#*, Deng, Y.#, Zhang, Z.#, Wang, Y., Gao, X., Liang, H., Li, Z., Wang, Q., Cheng, Y., Chen, Q., Huang, S., Pan, Y., Su, M., Lin, X., Niu, C., Chen, Y., Yang, W., Zhang, Y., Yan, Q., He, J.*, Zhao, J.*, Chen, L.*, Xiong, X.* (2024) An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS- CoV-2 spike. Cell Reports 43: 114265

3.    Chen, X.#, Huang, X.#, Ma, Q.#, Kuzmič, P.#, Zhou, B., Xu, J., Liu, B., Jiang, H., Zhang, W., Yang, C., Wu, S., Huang, J., Li, H., Long, C., Zhao, X., Xu, H., Sheng, Y., Guo, Y., Niu, C., Xue, L., Xu, Y., Liu, J., Zhang, T., Spencer, J., Deng, W., Chen, S.-H.*, Zhong, N.*, Xiong, X.*, Yang, Z.*, (2024) Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 with improved pharmacokinetics compared to nirmatrelvir. Nature Microbiology 9: 1075-1088;

4.    Yan, Q.#, Zhang, Y.#, Hou, R.#, Pan, W.#, Liang, H.#, Gao, X., Deng, W., Huang, X., Qu, L., Tang, C., He, P., Liu, B., Wang, Q., Zhao, X., Lin, Z., Chen, Z., Li, P., Han, J., Xiong, X.*, Zhao, J.*, Li, S.*, Niu, X.*, Chen, L.* (2023) Deep immunoglobulin repertoire sequencing depicts a comprehensive atlas of spike-specific antibody lineages shared among COVID-19 convalescents. Emerg Microbes Infect: 2290841

5.    Zhang, X.#, Li, Z.#, Zhang, Y.#, Liu, Y.#, Wang, J., Liu, B., Chen, Q., Wang, Q., Fu, L., Wang, P., Zhong, X., Jin, L., Yan, Q., Chen, L., He, J.*, Zhao, J.*, Xiong, X.* (2023) Disulfide stabilization reveals conserved dynamic features between SARS-CoV-1 and SARS-CoV-2 spikes. Life Sci Alliance

6.    Yu, H.#*, Liu, B.#, Zhang, Y.#, Gao, X.#, Wang, Q.#, Xiang, H.#, Peng, X.#, Xie, C.#, Wang, Y.#, Hu, P., Shi, J., Shi, Q., Zheng, P., Feng, C., Tang, G., Liu, X., Guo, L., Lin, X., Li, J., Liu, C., Huang, Y., Yang, N., Chen, Q., Li, Z., Su, M., Yan, Q., Pei, R., Chen, X., Liu, L., Hu, F., Liang, D., Ke, B., Ke, C.*, Li, F.*, He, J.*, Wang, M.*, Chen, L.*, Xiong, X.*, Tang, X.* (2023) Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. Nature Communications 14: 1058

7.    He, P.#, Liu, B.#, Gao, X.#, Yan, Q.#, Pei, R.#, Sun, J., Chen, Q., Hou, R., Li, Z., Zhang, Y., Zhao, J., Sun, H., Feng, B., Wang, Q., Yi, H., Hu, P., Li, P., Zhang, Y., Chen, Z., Niu, X., Zhong, X., Jin, L., Liu, X., Qu, K., Ciazynska, K.A., Carter, A.P., Briggs, J.A.G., Chen, J., Liu, J., Chen, X.*, He, J.*, Chen, L.*, Xiong, X.* (2022) SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. Nature Microbiology 7: 1635-1649

8.    Yan, Q., Hou, R., Huang, X., Zhang, Y., He, P., Zhang, Y., Liu, B., Wang, Q., Rao, H., Chen, X., Zhao, X., Niu, X., Zhao, J., Xiong, X.*, Chen, L.* (2022) Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants. Emerg Microbes Infect 11: 2749-2761

9.    Qu, K.#, Chen, Q.#, Ciazynska, K.A., Liu, B., Zhang, X., Wang, J., He, Y., Guan, J., He, J., Liu, T., Zhang, X., Carter, A.P., Xiong, X.*, Briggs, J.A.G.* (2022) Engineered disulfide reveals structural dynamics of locked SARS-CoV-2 spike. PLoS Pathogens 18: e1010583

10.  Xiong, X.#*, Qu, K.#, Ciazynska, K.A., Hosmillo, M., Carter, A.P., Ebrahimi, S., Ke, Z., Scheres, S.H.W., Bergamaschi, L., Grice, G.L., Zhang, Y., The CITIID-NIHR COVID-19 BioResource Collaboration, Nathan, J.A., Baker, S., James, L.C., Baxendale, H.E., Goodfellow, I., Doffinger, R., Briggs, J.A.G.* (2020) A thermostable, closed SARS-CoV-2 spike protein trimer. Nature Structural & Molecular Biology 27: 934-941

11.  Peukes, J.#, Xiong, X.#*, Erlendsson, S., Qu, K., Wan, W., Calder, L.J., Schraidt, O., Kummer, S., Freund, S.M.V., Krausslich, H.G., Briggs, J.A.G.* (2020) The native structure of the assembled matrix protein 1 of influenza A virus. Nature 587: 495-498

12.  Walls, A.C.#, Xiong, X.#, Park, Y.J., Tortorici, M.A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., Zambon, M., Rey, F.A., Corti, D., Veesler, D. (2019) Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Cell 176: 1026-1039.e1015

13.  Xiong, X., Tortorici, M.A., Snijder, J., Yoshioka, C., Walls, A.C., Li, W., McGuire, A.T., Rey, F.A., Bosch, B.-J., Veesler, D. (2018) Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric Infections. Journal of Virology 92: e01628-17

14.  Xiong, X.#, Corti, D.#, Liu, J.#, Pinna, D., Foglierini, M., Calder, L.J., Martin, S.R., Lin, Y.P., Walker, P.A., Collins, P.J., Monne, I., Suguitan, A.L., Jr., Santos, C., Temperton, N.J., Subbarao, K., Lanzavecchia, A., Gamblin, S.J., Skehel, J.J. (2015) Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody. Proc Natl Acad Sci U S A 112: 9430-9435

15.  Xiong, X., Xiao, H., Martin, S.R., Coombs, P.J., Liu, J., Collins, P.J., Vachieri, S.G., Walker, P.A., Lin, Y.P., McCauley, J.W., Gamblin, S.J., Skehel, J.J. (2014a) Enhanced human receptor binding by H5 haemagglutinins. Virology 456-457: 179-187

16.  Vachieri, S.G.#, Xiong, X.#, Collins, P.J., Walker, P.A., Martin, S.R., Haire, L.F., Zhang, Y., McCauley, J.W., Gamblin, S.J., Skehel, J.J. (2014) Receptor binding by H10 influenza viruses. Nature 511: 475-477

17.  Xiong, X., McCauley, J.W., Steinhauer, D.A. (2014) Receptor binding properties of the influenza virus hemagglutinin as a determinant of host range. Curr Top Microbiol Immunol 385: 63-91

18.  Xiong, X.#, Coombs, P.J.#, Martin, S.R.#, Liu, J., Xiao, H., McCauley, J.W., Locher, K., Walker, P.A., Collins, P.J., Kawaoka, Y., Skehel, J.J., Gamblin, S.J. (2013a) Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature 497: 392-396

19.  Xiong, X., Martin, S.R., Haire, L.F., Wharton, S.A., Daniels, R.S., Bennett, M.S., McCauley, J.W., Collins, P.J., Walker, P.A., Skehel, J.J., Gamblin, S.J. (2013) Receptor binding by an H7N9 influenza virus from humans. Nature 499: 496-499

20.  Xiong, X., Tuzikov, A., Coombs, P.J., Martin, S.R., Walker, P.A., Gamblin, S.J., Bovin, N., Skehel, J.J. (2013) Recognition of sulphated and fucosylated receptor sialosides by A/Vietnam/1194/2004 (H5N1) influenza virus. Virus Research 178: 12-14

21.  Lin, Y.P.#, Xiong, X.#, Wharton, S.A., Martin, S.R., Coombs, P.J., Vachieri, S.G., Christodoulou, E., Walker, P.A., Liu, J., Skehel, J.J., Gamblin, S.J., Hay, A.J., Daniels, R.S., McCauley, J.W. (2012) Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A 109: 21474-21479

22.    Xiong, X., Bromley, E.H., Oelschlaeger, P., Woolfson, D.N., Spencer, J. (2011) Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface loops direct the activity of a Qnr protein from a gram-negative bacterium. Nucleic Acids Research 39: 3917-3927